Last reviewed · How we verify
Thalidomide (100mg)
Thalidomide acts as an immunomodulatory agent, inhibiting the release of tumor necrosis factor-alpha (TNF-alpha) and other pro-inflammatory cytokines.
Thalidomide acts as an immunomodulatory agent, inhibiting the release of tumor necrosis factor-alpha (TNF-alpha) and other pro-inflammatory cytokines. Used for Multiple myeloma, Erythema nodosum leprosum.
At a glance
| Generic name | Thalidomide (100mg) |
|---|---|
| Also known as | thalido, Thalidomide, Thalomid, Fan Ying Ting, Group 1 |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Drug class | Immunomodulator |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Thalidomide also has anti-angiogenic properties, inhibiting the formation of new blood vessels that supply tumors. Additionally, it can induce apoptosis in cancer cells and modulate the immune response to promote anti-tumor activity.
Approved indications
- Multiple myeloma
- Erythema nodosum leprosum
Common side effects
- Neuropathy
- Fatigue
- Constipation
- Dizziness
- Headache
Key clinical trials
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. (PHASE2)
- Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis (PHASE3)
- EDOCH Alternating With DHAP for New Diagnosed Younger MCL (PHASE4)
- Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia (PHASE2)
- Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH (PHASE2)
- Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH (PHASE2)
- Long Term Beta Thalassemia Treatment: Findings From The Extension Period (PHASE2)
- Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: